E
Eltrombopag
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Eltrombopag
General information
Subsidy Information and Financing Scheme
[MAF] Eltrombopag Tablet 25 mg, 50 mg
Treatment of immune thrombocytopenia lasting six months or longer from diagnosis in patients who are intolerant or refractory to other treatments (e.g. corticosteroids, immunosuppressants).
Treatment of severe aplastic anaemia in patients who are refractory to immunosuppressive therapy (comprising horse anti-thymocyte globulin plus ciclosporin for at least 3 months) and have marrow cellularity <25% (or 25 to 50% with <30% residual haematopoietic cells), with at least 2 of the following:
• neutrophils <0.5 x 109/l
• platelets <20 x 109/l
• reticulocyte count <20 x 109/l (<60 x 109/l for automated reticulocyte counting)
Drug Guidance for Subsidy
04/01/2022 Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
Eltrombopag 25 mg and 50 mg tablets for treating:
immune thrombocytopenia lasting six months or longer from diagnosis in patients who are intolerant or refractory to other treatments (e.g. corticosteroids, immunosuppressants); and
severe aplastic anaemia in patients who are refractory to immunosuppressive therapy (comprising horse anti-thymocyte globulin plus ciclosporin for at least three months) and have marrow cellularity <25% (or 25 to 50% with <30% residual haematopoietic cells), with at least two of the following:
neutrophils <0.5 x 109/l
platelets <20 x 109/l
reticulocyte count <20 x 109/l (<60 x 109/l for automated reticulocyte counting).
Eltrombopag should be prescribed by a haematologist with experience in managing immune thrombocytopenia and severe aplastic anaemia.
Subsidy status
[R] Eltrombopag 25 mg and 50 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
[NR] MAF assistance does not apply to the use of eltrombopag for treating newly diagnosed severe aplastic anaemia.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 25 mg |
|
Tablet 50 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.